CC BY-NC-ND 4.0 · AJP Rep 2020; 10(01): e87-e92
DOI: 10.1055/s-0040-1705173
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Abortion for Fetal Genetic Abnormalities: Type of Abnormality and Gestational Age at Diagnosis

Tracy B. Grossman
1   Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York
,
Stephen T. Chasen
1   Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York
› Author Affiliations
Further Information

Publication History

04 November 2019

20 December 2019

Publication Date:
16 March 2020 (online)

Abstract

Background Advances in genetic screening can identify patients at high risk for common genetic conditions early in pregnancy and can facilitate early diagnosis and early abortion. Less common abnormalities might only be diagnosed with invasive testing is performed after structural abnormalities are identified.

Objective Our objective was to compare gestational age (GA) at diagnosis and abortion for genetic abnormalities identified based on screening with abnormalities that were not discovered after screening.

Study Design All prenatal diagnostic procedures from 2012 to 2017 were reviewed, and singleton pregnancies terminated following diagnosis of genetic abnormalities were identified. Cases diagnosed as the result of screening tests were compared with remaining cases. Conditions were considered “screened for” if they can be suspected by cell-free DNA testing, biochemistry, carrier screening, or if the patient was a known carrier of a single-gene disorder. When abnormal karyotype, microarray, or Noonan's syndrome was associated with abnormal NT, these cases were considered “screened for.” GA at abortion was the primary outcome. Fisher's exact test and Mann–Whitney's U test were used for statistical comparison.

Results In this study, 268 cases were included. A total of 227 (85%) of abortions were performed for “screened for” disorders, with 210 (93%) of these for karyotype abnormalities, 5 (2%) for microarray abnormalities, and 12 (5%) for single-gene disorders. Forty-one (15%) of abortions were performed for conditions not included in screening, with 8 (19%) of those for karyotype abnormalities, 25 (61%) for microarray abnormalities, and 8 (19%) for single-gene disorders. Invasive testing and abortion occurred at earlier median GA for those with conditions that were screened for: 122/7 versus 155/7 weeks, p ≤0.001 and 135/7 versus 200/7 weeks; p ≤0.001.

Conclusion Most abortions were for abnormalities that can be suspected early in pregnancy. As many structural abnormalities associated with rare conditions are not identifiable until the mid-trimester, prenatal diagnosis and abortion occurred significantly later. Physicians and patients should be aware of the limitations of genetic screening.

 
  • References

  • 1 Nussbaum RL, McInnes RR, Willard HF. Principles of clinical cytogenetics and genome analysis. In: Thompson & Thompson Genetics in Medicine. Philadelphia, PA: Elsevier; 2016
  • 2 Practice Bulletin No. 163 Summary: screening for fetal aneuploidy. Obstet Gynecol 2016; 127 (05) 979-981
  • 3 Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: esteele@smfm.org. SMFM statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. Am J Obstet Gynecol 2015; 213 (06) 753-754
  • 4 Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Prenatal aneuploidy screening using cell-free DNA. Am J Obstet Gynecol 2015; 212 (06) 711-716
  • 5 Microarrays and next-generation sequencing technology: the use of advanced genetic diagnostic tools in obstetrics and gynecology. Obstet Gynecol 2016; 128 (06) 262-268
  • 6 Dugoff L, Norton ME, Kuller JA. The use of chromosomal microarray for prenatal diagnosis. J Obstet Gynecol 2016; 215 (04) B2-B9
  • 7 American College of Obstetricians and Gynecologists Committee on Genetics. Committee opinion no. 690: Carrier screening in the age of genomic medicine. Obstetric Gynecol 2017; 129 (03) e35-e40
  • 8 American College of Obstetricians and Gynecologists Committee on Genetics. Carrier screening for genetic conditions. Obstet Gynecol 2017; 129 (03) e41-e55
  • 9 ACOG Technology Assessment in Obstetrics and Gynecology No 14: Modern genetics in obstetrics and gynecology. Obstet Gynecol 2018; 123: e143-e168
  • 10 Davis AR, Horvath SK, Castaño PM. Trends in gestational age at time of surgical abortion for fetal aneuploidy and structural abnormalities. Am J Obstet Gynecol 2017; 216 (03) 278.e1-278.e5
  • 11 Hume H, Chasen ST. Trends in timing of prenatal diagnosis and abortion for fetal chromosomal abnormalities. Am J Obstet Gynecol 2015; 213 (04) 545.e1-545.e4
  • 12 ACOG Practice Bulletin No. 135: second-trimester abortion. Obstet Gynecol 2013; 121 (06) 1394-1406
  • 13 Karim JN, Roberts NW, Salomon LJ, Papageorghiou AT. Systematic review of first-trimester ultrasound screening for detection of fetal structural anomalies and factors that affect screening performance. Ultrasound Obstet Gynecol 2017; 50 (04) 429-441
  • 14 Jones RK, Jerman J. Abortion incidence and service availability in the United States, 2014. Perspect Sex Reprod Health 2017; 49 (01) 17-27
  • 15 Wapner RJ, Martin CL, Levy B. , et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012; 367 (23) 2175-2184